Amphiregulin (AREG) is a ligand of the epidermal growth factor (EGF) receptor and may play a role in the development of cirrhosis and hepatocellular carcinoma in patients infected with hepatitis C virus (HCV). AREG showed an enhanced expression in HCV-infected human hepatoma cells according to gene array analysis. Therefore, we addressed the question about the role of AREG in HCV infection. AREG expression level was elevated in hepatoma cells containing a subgenomic HCV replicon or infected by HCV. Using a reporter assay, AREG promoter activity was found to be upregulated upon HCV infection. The enhanced AREG expression in hepatoma cells was partly caused by dsRNAs, HCV NS3 protein and autocrine stimulation. AREG was able to activate cellular signalling pathways including ERK, Akt and p38, promote cell proliferation, and protect cells from HCV-induced cell death. Further, knockdown of AREG expression increased the efficiency of HCV entry, as proven by HCV pseudoparticles reporter assay. However, the formation and release of infectious HCV particles were reduced by AREG silencing with a concomitant accumulation of intracellular HCV RNA pool, indicating that the assembly and release of HCV progeny may require AREG expression. Blocking the MAPK-ERK pathway by U0126 in Huh7.5.1 cells had a similar effect on HCV replication. In conclusion, HCV infection leads to an increase in AREG expression in hepatocytes. AREG expression is essential for efficient HCV assembly and virion release. Due to the activation of the cellular survival pathways, AREG may counteract HCV-induced apoptosis of infected hepatocytes and facilitate the development of liver cirrhosis and hepatocellular carcinoma.
INTRODUCTION
Hepatitis C virus (HCV) infection of hepatoma cells induces wide-ranging changes of gene expression in host cells. Microarray, proteomic analysis and RNA sequencing enabled researchers to identify large number of genes involved in cell proliferation, apoptosis and cytokine/ growth factor signalling that are modulated by HCV infection (Blackham et al., 2010; Diamond et al., 2007; Fang et al., 2006a, b; Walters et al., 2009; Woodhouse et al., 2010) . It is not yet well understood how these host factors participate in HCV life cycle from viral entry to assembly/ release of viral progenies, or how they contribute to the pathogenesis of HCV infection.
Amphiregulin (AREG) is a ligand of the epidermal growth factor (EGF) receptor and is involved in the regulation of cell growth and apoptosis. AREG mRNA is expressed in many normal tissues, including placenta, testis, pancreas, spleen, kidney, lung, breast, ovary and colon (Plowman et al., 1990) . It has been found to play an important role in the mammary gland development, breast cancer and colorectal cancer (Berquin et al., 2001; Bordoli et al., 2010; McBryan et al., 2008; Yotsumoto et al., 2008) . Recently, AREG has also been identified as one of the 10-gene signatures in close association with the occurrence of liver metastasis in colorectal cancer patients (Watanabe et al., 2010) . The expression of AREG in normal livers is undetectable; however, it is induced during acute and chronic liver injury. AREG is an early response growth factor during liver regeneration (Berasain et al., 2005a; Pardo-Saganta et al., 2009) . It can activate survival pathways such as AKT and ERK signal, protect liver cells from apoptosis and abrogate Fas-mediated liver injury in mice (Berasain et al., 2005b) . It also contributes to the transformed phenotype of human hepatocellular carcinoma cells (Castillo et al., 2006) . Recently, AREG has been proven to be able to promote the growth and survival of fibrogenic cells and to mediate the expression of fibrogenic mediators (Perugorria et al., 2008) . Here, we report that HCV infection induces the AREG expression in hepatoma cells and liver tissue in patients. We examined the role of AREG expression for HCV infection in the cell model. The results obtained here suggest that AREG promotes cell survival after HCV infection and is required for efficient assembly and release of infectious viral particles.
RESULTS
AREG expression in Huh7.
cells and liver tissue during HCV infection
The expression of many genes related to cell cycle control, apoptosis, oxidative stress and cytokines/growth factors was changed in Huh7.5.1 cells after infection with JFH-1, consistent with the previous report . Among the relevant genes, AREG was one of the most significantly upregulated genes, as indicated by three independent gene array analyses. Therefore, AREG expression in cells was examined in Con1 cells with the subgenomic HCV replicon and Huh7.5.1 after HCV particles in cell culture (cc) infection. The AREG mRNA level in Con1 cells was twofold higher than that in the parental Lunet cells (Fig. 1a) . Suppression of HCV replication and gene expression in Con1 cells by specific small interfering siRNA targeted to HCV or IFN-a treatment downregulated AREG expression (Fig. 1b,  c) . The decrease of AREG expression induced by IFN-a treatment was not due to the pleiotropic effect of IFN-a, as IFN-a treatment did not change AREG expression in Huh7-Lunet cells ( Supplementary Fig. S1 , available in JGV Online). These results indicated that the replication of the subgenomic HCV replicon is associated with an elevated AREG expression. Next, the AREG expression level in Huh7.5.1 cells was determined after HCVcc infection. Huh7.5.1 cells were infected with J399EM at an m.o.i of 0.1. Total RNAs were collected at different time points up to 120 h after HCVcc infection and subjected to real-time RT-PCR determination of AREG mRNAs. The AREG mRNA level increased significantly 72 h after infection when HCV RNA replicated to a high level in cells and new HCVcc were produced and released (Fig. 1d) . AREG protein levels in the supernatant after HCVcc infection were detected by ELISA (Fig. 1e) . AREG protein was detected in culture supernatants of Huh7.5.1 cells without HCV infection and its level increased gradually with the duration of culturing. An enhanced AREG release into culture media occurred at 72 h after HCV infection, in agreement with the upregulated AREG mRNA levels. Finally, the effect of HCVcc infection on the AREG promoter was examined. The AREG promoter region was cloned into pGL3 luciferase reporter vectors to generate the reporter plasmid pGL3-AR. Two plasmids pGL3-AR and pRL-TK reporter plasmid (Promega) were co-transfected into Huh7.5.1 cells. Cells were infected with HCVcc at an m.o.i. of 0.1, 24 h after transfection and incubated for 72 h. The dual luciferase assay was performed to determine the luciferase activities. AREG promoter was active to direct luciferase expression in Huh7.5.1 cells and HCV infection significantly enhanced AREG promoter activity (Fig. 1f) . In comparison, Sendai virus infection led to an enhanced AREG expression in Huh7-Lunet cells but not in Huh7.5.1 cells, indicating that the viral components of HCV may specifically stimulate AREG expression in Huh7.5.1 cells ( Supplementary Fig. S2 , available in JGV Online and see below).
The elevation of AREG expression in liver tissues from chronically HCV-infected patients was measured (Fig. 1g) . In liver tissue from patients without HCV infection, AREG was only present at very low levels of less than 1610 3 copies per 10 6 b-actin mRNAs. AREG expression was significantly elevated to an average level of 4610 3 copies per 10 6 b-actin mRNAs in liver tissue from patients with HCV infection (Fig. 1g) . Thus, HCV replication and infection is associated with an upregulated AREG expression in hepatoma cells and liver tissue from patients.
AREG upregulation in hepatoma cells by dsRNAs and HCV NS3 protein
The upregulation of AREG expression occurred at a late time point of HCV infection and therefore may be stimulated by viral components. During HCV infection the stem-loop dsRNA structure at the 59 untranslated region of HCV RNA and other dsRNA intermediates may act through cellular pathways and trigger AREG expression. We addressed this question by using polyinosinic-polycytidylic acid (poly IC), a synthetic dsRNA polymer to mimic the situation. AREG expression in Huh7-Lunet cells increased over threefold at 6 h after transfection with poly IC and returned to the normal level by 48 h (Fig. 2a) . The induction of AREG expression by poly IC was in a dose-dependent manner (Fig. 2b) . However, poly IC failed to induce AREG expression in Huh7.5.1 cells ( Supplementary Fig. S3 , available in JGV Online). Thus, HCV proteins may be responsible for AREG upregulation in Huh7.5.1 with Rig-I deficiency. Fig. 2(c, d) show that co-transfection with the expression vector of HCV NS3 protein stimulated the reporter gene expression under the control of AREG promoter in Huh7.5.1 cells in a dose-dependent manner, while other HCV proteins like HCV core did not have a significant effect. Transfection of the expression vector of HCV NS3 protein led to an increased AREG expression in Huh7.5.1 cells (Fig. 2e) . In addition, an incubation of Huh7-Lunet and Con1 cells with recombinant human AREG (rhAREG) increased AREG expression in cells, consistently with the autocrine regulation of AREG described previously (Fig. 2f, Supplementary Fig. S4 , available in JGV Online).
AREG activates the MAPK-ERK pathway and stimulates hepatoma cell growth.
AREG is known as a member of the EGF family and acts through the EGF receptor (Plowman et al., 1990) . Therefore, we examined the ability of AREG to activate survival pathways in Huh7-Lunet cells and promote cell proliferation. Western blot results showed that rhAREG induced the phosphorylation of ERK and AKT in Huh7-Lunet cells (Fig. 3a) , similar to EGF. Further, HCVcc Firefly luciferase and Renilla luciferase activities were determined by using the dual luciferase reporter assay system (Promega). (a-f) Three independent triplicate experiments were performed. (g) AREG mRNA levels in patients without and with HCV infection. Total RNAs were prepared from liver tissue samples from patients and subjected to real-time RT-PCR to determine AREG mRNA levels. The relative levels of AREG mRNAs were given as the ratio to the copy numbers of b-actin mRNAs.
infection reduced cell viability, as shown previously (Han et al., 2009 ) and confirmed by WST-1 assay and determination of cytoplasmic histone-associated DNA fragments (Fig. 3b, c) . Exogenous rhAREG added to the cell culture slightly increased the cell viability and reduced the DNA fragmentation in cells. Consistently, a neutralization of AREG by a specific anti-AREG antibody led to a more severe loss of cell viability and increased DNA fragmentation after HCVcc infection (Fig. 3b, c) . Thus, AREG apparently plays a role in cell survival that is often essential for efficient viral replication. The stimulation of cell growth progression by AREG was confirmed by cell cycle analysis. Huh7.5.1 cells were first treated with Aphidicolin and arrested at the G1 phase of the cell cycle.
The cell cycle progression resumed after removal of Aphidicolin (Fig. 3d, top) . The presence of rhAREG promoted cell cycle progression, especially from the G2/ M phase to the G1 phase at 12 h after Aphidicolin removal ( Fig. 3d, 
bottom).
HCVcc infection led to the stimulation of cellular pathways including the MAPK-ERK pathway. As shown in Fig. 4 (a), HCVcc caused ERK, AKT and p38 phosphorylation in Huh7.5.1 at 24 and 48 h after infection. We asked whether AREG expression was involved in the action of these pathways. Both blocking AREG by the neutralizing antibody or incubation of Huh7.5.1 with an EGFR inhibitor PD153035 could only marginally reduce ERK and p38 phosphorylation by HCVcc infection, as compared with the MAPK-ERK kinase inhibitor U0126 (Fig. 4b, c) . Only the phosphorylation of AKT appeared to be reduced by PD153035 and antibody to AREG. These results are consistent with the fact that HCV may stimulate these pathways through other such intracellular pathways. However, AREG was required to stimulate the AKT survival pathway.
Role of AREG in Con1 cells with HCV subgenomic replicon
The upregulation of AREG by HCVcc infection raised the question as to whether AREG expression plays a role in the HCV life cycle. Thus, the role of AREG in HCV replication was examined by siRNA knockdown experiments.
First, the knockdown efficiency of siRNA for AREG, siAREG, was tested. Huh7.5.1 cells were transfected with siAREG and an unrelated siRNA, siNC. AREG mRNA levels and AREG protein in the supernatant were measured by real-time RT-PCR and ELISA, respectively. As shown in Fig. 5(a, b) , transfection of siAREG significantly reduced AREG expression in Huh7.5.1 cells. The base line level of AREG mRNA in Huh7.5.1 cells was measured at about 1.5610 4 copies per 10 6 b-actin mRNA. Transfection with siAREG led to a decrease of AREG mRNA level to 8 % of the base line. At the same time, AREG protein concentration in cell culture supernatants was reduced from 200 to 53 ng ml 21 , by siAREG. Thus, silencing of AREG mRNAs by siRNA was efficient. In addition, the viability of Huh7.5.1 cells was not affected by the silencing of AREG, as determined by WST-1 assay (Fig. 5c) .
Using Con1 cells, the role of AREG in HCV replication was examined. After the reseeding of transfected Con1 cells, the HCV RNA level remained low, while the HCV RNA level in cells transfected with control siRNAs increased gradually as known previously (Fig. 6a) . In parallel, the expression of HCV NS5A protein was also reduced by the knockdown of AREG (Fig. 6b) . Consistently, blocking AREG by a neutralizing anti-AREG antibody or by an EGFR inhibitor PD153035 reduced HCV RNA level in Con1 cells (Fig. 6c) . Although the addition of exogenous rhAREG into the cell culture did not affect HCV replication, it can restore HCV RNA level in Con1 cells transfected with siAREG, but not in cells transfected with siHCV (Fig. 6d, Supplementary  Fig. S5 , available in JGV Online). Thus, the upregulation of AREG expression facilitated HCV replication in Con1 cells.
Silencing of AREG facilitated the early steps of HCV infection and reduced the production of HCV viral particles Next, we determined the effect of siAREG on viral entry by a transduction experiment with HCVpp. HCVpp were generated by co-transfection of pNL4.3.lucR-E-and pE1E2 into 293T cells and used to transduce Huh7.5.1 cells treated with siAREG and control siRNA. After 72 h, the HCVppmediated luciferase expression was measured and showed a 2.5-fold increase after the silencing of AREG as compared with the control, suggesting a higher efficiency of viral entry since the transduced reporter RNA could not be amplified in cells (Fig. 7a) . To investigate the effect of AREG on HCVcc infection, Huh7.5.1 cells were transfected with siAREG, then reseeded into 24-well plates 48 h thereafter, and subsequently infected 24 h later with J399EM at an m.o.i of 0.1. HCV RNA copy numbers and viral titres in the supernatant and in cells 72 h post-infection were determined separately. In contrast, the HCV RNA level and HCV titre in culture supernatants of siAREG-treated cells were reduced (Fig. 7b,  c) . The quantification of the intracellular HCV RNA pool showed an accumulation of HCV RNA in cells after AREG silencing. Despite the higher level of intracellular HCV RNA, the intracellular HCV titre did not differ between siAREGtreated and control Huh7.5.1 cells, suggesting that HCV assembly and release of HCV progeny was slowed down by AREG silencing (Fig. 7d, e) . The MAPK-ERK inhibitor U0126 affects HCV assembly and release
The knockdown of AREG may prevent or attenuate the activation of cellular pathways during HCV infection and therefore influence HCV life cycle. We tested this hypothesis by using a chemical inhibitor U0126 to block the MAPK-ERK pathway, the major pathway activated by AREG. Huh7.5.1 cells were pre-treated with U0126 at a concentration of 5 mM before infection with HCVcc at an m.o.i of 0.1. The HCV RNA and viral titre in supernatant and in cells were detected separately at an indicated time point postinfection. The results showed that pre-incubation with U0126 led to a decrease of intracellular and extracellular HCV RNA copy numbers (Fig. 8) . Particularly, the titre of released infectious HCV progeny was strongly reduced by treatment with U0126, indicating the important role of the MAPK-ERK pathway for this process.
DISCUSSION
Host genes involved in viral replication have also been identified by several groups using RNA silencing screening (Berger et Vaillancourt et al., 2009) . In the present study, we focused on AREG, a ligand of the EGFR. AREG is synthesized as a transmembrane glycoprotein precursor. The mature soluble AREG was released through a proteolytic cleavage by tumour necrosis factor-alpha converting enzyme (TACE), a member of the disintegrin and metalloproteinase (ADAM) family (Kasina et al., 2009 ). This fact probably leads to an unsynchronized change of AREG mRNA and protein levels, as shown in Fig. 1 . AREG expression is also under the regulation of the MAPK-ERK pathway in an autocrine manner (Castillo et al., 2006) . HCV infection activates the MAPK-ERK pathway (Fig. 4a) , and may lead to enhanced AREG expression in hepatoma cells and in the liver tissue of patients. AREG may play a role in the protection of cells against apoptosis during HCV infection, through the activation of survival pathways in hepatoma cells. It is already known that HCV infection leads to cytopathic effects and apoptosis of infected cells (Deng et al., 2008; Joyce et al., 2009; Walters et al., 2009) , possibly through TGF-b1 signalling. AREG was shown to block TGFb1-mediated apoptosis (Castillo et al., 2006) and, therefore, may counteract the cytopathic effect of HCV infection. In general, the survival pathways are activated in different cell systems with HCV infection (Brenndörfer et al., 2009; Burdette et al., 2010; Mannová & Beretta, 2005) . In our study, we found that HCV infection itself activates MAPK-ERK independently on AREG. However, the activation of the Akt survival pathway requires the action of AREG, as the block of AREG or EGFR abolished the enhanced phosphorylation of Akt. AREG expression appears to be a factor for tumour development, as reported for breast cancer (Lamber et al., 2010; Wang et al., 2008) and colorectal cancer. Recently, AREG is proposed to be a growth factor involved in hepatocarcinogenesis (Berasain et al., 2007; Castillo et al., 2006) . AREG was reported to be responsible for the transformed phenotype of hepatoma cells previously (Castillo et al., 2006) and induces the alternative splicing of p73, leading to the formation of its oncogenic isoform Ex2p73 in human HCCs . It is likely that AREG plays a general protective role in liver injury, but also promotes the survival of tumour cells.
In this study, we demonstrated that AREG expression is important for the HCV life cycle. The early entry step of HCV infection was apparently facilitated after the knockdown of AREG, as shown by HCVpp transduction in Huh7.5.1 cells. However, the later steps of the assembly and release of viral particles were affected by AREG silencing, suggesting the importance of AREG in the late stage of HCV infection. This would also explain the upregulation of AREG expression at a late time point after HCV infection. In addition, AREG is apparently required for the efficient HCV replication, as shown in Fig. 6 . Due to the complexity of AREG actions, it is not completely clear how AREG acts on the HCV life cycle. A recent publication indicated that EGFR is a host factor for HCV entry (Lupberger et al., 2011) . Activation of EGFR by EGFR ligands, EGF and TGF-a, could enhance HCV entry, possibly at the postbinding steps by promoting CD81-CLDN1 co-receptor interactions and membrane fusion. Another publication (Baillo et al., 2011) reported that AREG knockdown could not abolish the proliferation of breast cancer cells, since AREG knockdown led to an elevated steady-state of EGFR protein and an accumulation of EGFR at the plasma membrane. It is likely that AREG facilitates the virus entry through EGFR functions. As shown in the present study, AREG was able to activate MAPK-ERK, Akt and other pathways in Huh7.5.1 cells. The blockade of MAPK-ERK pathways had a similar negative effect on HCV assembly and virion release, suggesting that the MAPK-ERK pathway may at least partly mediate AREG action on HCV replication. Both experiments described in Figs 7 and 8 indicated consistently that the assembly and virion release were affected if AREG expression or the MAPK pathway were blocked. Though an enhanced entry of HCV occurred in siAREG-transfected cells, the HCV assembly and virion release was decreased. Therefore, the negative effect of AREG silencing on the late HCV replication process was dominant and not influenced or compensated by the efficient viral entry. In a recent report, the treatment of HCV-infected cells with an inhibitor of late endosome movement U18666A caused a reduced extracellular HCV RNA level and an increased intracellular HCV RNA level (Lai et al., 2010) . Apparently, HCV egress requires the microtubule-dependent motility of early to late endosomes. Thus, it will be worthy to study the regulation of HCV assembly and virion release by AREG signalling.
METHODS
Cell lines, plasmids and reagents. Huh7-Lunet cells (kindly provided by Professor Dr Ralf Bartenschlager) and Huh7.5.1 cells (kindly provided by Professor Dr Frank Chisari) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % FBS, 2 mmol glutamine l
21
, 100 U penicillin ml 21 and 100 U streptomycin ml 21 at 37 uC in a 5 % CO 2 atmosphere. The subgenomic HCV replicon pFKI389neo/NS3-39 was kindly provided by Professor Dr Ralf Bartenschlager. Con1 cells harbouring the subgenomic HCV replicon were derived from Lunet cells maintained in the same medium for Lunet cells supplemented with 0.5 mg G418 (Cytogen) ml
. rhAREG was purchased from R&D System and used at a concentration of 50-200 ng ml 21 according to the literature (Castillo et al., 2006 Pardo-Saganta et al., 2009) . The inhibitors of the MAPK-ERK pathway PD153035 and U0126 were provided from Merck. Aphidicolin, poly IC and a monoclonal mouse anti-actin (a-Sarcomeric) antibody were purchased from Sigma-Aldrich. Antibodies to ERK1 (K-23) and pERK (E-4) from Santa Cruz Biotechnology and the secondary antibodies peroxidase affinipure goat anti-mouse IgG (H+L) and peroxidase affinipure goat anti-rabbit IgG (H+L) from Jackson ImmunoResearch Inc. were used in this study.
Liver samples from patients. From 2001 to 2008, liver biopsies were obtained from patients with HCV infection (n59, seven males, two females, with mean age of 57 years ranging from 15 to 80 years) or without HCV infection but other liver diseases like hepatitis B virus infection and autoimmune liver diseases (n512, five males, seven females, with mean age of 62 years ranging from 37 to79 years) in the surgical department of the University Hospital of Essen, Germany. Tissue samples were snap frozen in liquid nitrogen immediately and then stored at 280 uC until use. The study was approved by the local ethics committee and all patients provided written informed consent.
Reporter plasmids and reporter assay. The reporter plasmids pGL3-basic and pRL-TK were purchased from Promega. A new reporter, pGL3-AR, was generated by cloning the AREG promoter sequence into the multiple cloning site of pGL3-basic. The primers The Firefly luciferase and Renilla luciferase activity were measured 72 h post-infection by using a dual luciferase reporter assay system (Promega). All reporter assays were repeated at least three times.
Generation of HCVpp and HCVpp transduction. The plasmid pNL4.3.lucR-E-expressing all human immunodeficiency virus proteins except Env, Vpr and Nef was described previously (Connor et al., 1995) . The plasmid pE1E2 expressing HCV E1E2 glycoproteins was kindly provided by Dr Jin Zhong (Li et al., 2011) . 293T cells were seeded into six-well plates at a density of 3610 5 cells per well 1 day before transfection. Cells were transfected with pNL4.3.lucR-E-and pE1E2 plasmid at a ratio of 4 : 1 using lipofectamine 2000 (Invitrogen). After transfection (48 h), culture supernatants of transfected cells were collected and filtered with a 0.45 mm filter (Millipore). The HCVpp stock was stored at 280 uC before use.
For the HCVpp transduction assay, Huh7.5.1 cells were seeded into 96-well plates at a density of 5¾10 3 cells per well in 100 ml DMEM containing 10 % FBS. Twenty-four hours later, the medium was replaced with 100 ml of HCVpp stock. After 6 h incubation at 37 uC, HCVpp containing medium was discarded and fresh medium was added to the wells. Three days later, luciferase assay was performed using Steady-Glo Luciferase Assay kit (Promega). Steady-Glo reagent (100 ml) was added to each well and incubated for 5 min and luminescence was measured with a luminometer (Promega).
Generation and infection of infectious HCVcc. HCVcc of JFH-1 and an HCV reporter strain J399EM with an EGFP insertion in NS5A on JFH1 backbone were produced and used for the infection of Huh7.5.1 cells as described previously (Han et al., 2009) . The infectious HCV titres in culture supernatants and cell lysates were determined by the end-point dilution assay described by Lindenbach (2009) .
RNA extraction and quantification of HCV RNA by real-time RT-PCR. Total RNAs from cultured cells and HCV RNA in culture supernatants were extracted using TRIzol and TRIzolLS (Invitrogen) according the manufacturer's instructions, respectively. The quantification of HCV RNA was performed by one step real-time RT-PCR using QuantiFast SYBR Green RT-PCR kit (Qiagen) and normalized against the copy numbers of human b-actin mRNAs, using primer given in Supplementary Table S1 .
Western blot. Western blot analysis using specific antibodies was performed as described previously (Han et al., 2009) .
AREG ELISA. Human AREG ELISA kits were purchased from RayBio, Inc. to determine AREG concentrations in cell culture supernatants according the manufacturer's instructions.
WST-1 assay for assessment of cell viability and detection of cell apoptosis. The viability of Huh7.5.1 cells after HCV infection was determined by the Cell Proliferation reagent kit I (WST-1; Roche Diagnostics). Huh7.5.1 cells were infected with mock or HCVcc and reseeded into 96-well plates 48 h post-infection and treated with different reagents for an additional 48 h. WST-1 reagents were added to the medium and incubated for 2 h in 37 uC. The absorbance at 450 nm was measured by a photometer.
The apoptosis of Huh7.5.1 cells after HCV infection were measured by using a Cell Death Detection ELISAPlus kit (Roche) according to the manufacturer's introduction. This assay was based on the determination of cytoplasmic histone-associated DNA fragments.
Cell cycle analysis by propidium iodide (PI). For cell cycle analysis, Lunet cells were treated with 10 ng Aphidicolin ml 21 for 18 h for cell cycle synchronization. The cells were washed three times with PBS to remove Aphidicolin and release cell cycle arrest. AREG was added to the medium immediately. The cells were harvested every 4 h and incubated in PBS containing 20 mg PI ml 21 , 200 mg RNase A ml 21 and 0.1 % Triton X-100 (BD Biosciences) at 37 uC for 20 min. 
